

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/apm-22-270	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	
3	What data in particular will be shared?	Our results indicate that M2BPGi is a single indicator of chronic liver disease status, including both ALBI grade and CONUT score.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Five years within the publication date, since survival data may be updated over time.
7	To whom will you share the data?	Hepatologists who are interested in studies of this study
8	For what type of analysis or purpose?	In this single-center study, we aimed to clarify the clinical usefulness of the novel noninvasive biomarker of hepatic fibrosis, Mac-2-binding protein glycosylation isomer (M2BPGi), in patients with chronic liver disease.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: toruishi@ngt.saiseikai.ot.jp.
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.